CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The SCIDNET project aims to advance gene therapy for severe combined immunodeficiency, a critical immune disorder. It seeks to provide curative options for various forms of SCID through clinical trials and regulatory processes.
Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development.
Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is given.
Treatment options are limited to allogeneic haematopoietic stem cell transplantation and autologous stem cell gene therapy.
Over the last 15 years, gene therapy for two forms of SCID (SCID-X1 and ADA SCID) has shown significant safety and efficacy in correcting th…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Heidelberg
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Italy, Milano
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
